Peptides for opioid use disorder

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Opioid Use Disorder: Mitigating Withdrawal and Cravings Opioid Use Disorder (OUD) affects over 3 million Americans, with overdose deaths exceeding 100,000 annually, highlighting a profound public health crisis [1]. While medication-as...

Peptides for Opioid Use Disorder: Mitigating Withdrawal and Cravings

Opioid Use Disorder (OUD) affects over 3 million Americans, with overdose deaths exceeding 100,000 annually, highlighting a profound public health crisis [1]. While medication-assisted treatments (MAT) like buprenorphine, methadone, and naltrexone are effective, many individuals struggle with persistent cravings, severe withdrawal symptoms, and high rates of relapse. Peptides offer a novel therapeutic approach by modulating endogenous opioid systems, stress responses, and neuroinflammation, potentially enhancing recovery outcomes and mitigating the long-term effects of opioid exposure.

The neurobiology of OUD is characterized by profound adaptations in the brain's reward system, particularly the mu-opioid receptor system, and dysregulation of stress and anti-stress pathways [2]. Endogenous opioid peptides, such as endorphins, enkephalins, and dynorphins, naturally modulate pain, mood, and reward. In OUD, the balance of these endogenous systems is severely disrupted, contributing to the intense dysphoria and cravings experienced during withdrawal. Modulating these systems, or supporting their recovery, is a key therapeutic target.

Oxytocin, often termed the "social hormone," has been extensively investigated for its potential to reduce opioid cravings and withdrawal symptoms. Its role in social bonding and stress regulation suggests it could mitigate the social deficits and heightened stress reactivity often seen in OUD. Studies indicate that intranasal oxytocin can modulate dopamine release in reward pathways, reduce anxiety, and directly attenuate opioid-like withdrawal symptoms [3]. For instance, a study involving individuals with OUD found that intranasal oxytocin significantly reduced self-reported opioid cravings and anxiety [4]. Clinical trials are exploring intranasal oxytocin (typically at doses of 24 IU to 40 IU, administered once or twice daily) as an adjunctive therapy to support abstinence and reduce cravings. You'll find that oxytocin helps to rebalance the stress response and reduce the emotional distress associated with opioid withdrawal, which can be critical for sustained recovery.

BPC-157, a stable gastric pentadecapeptide, is primarily recognized for its regenerative and cytoprotective properties. However, emerging research highlights its significant influence on the central nervous system, particularly its modulatory effects on the dopamine and opioid systems [5]. Animal studies indicate that BPC-157 can counteract morphine-induced analgesia and dopamine system dysregulation, suggesting a potential role in managing opioid-related neuroadaptations [6]. Its neuroprotective, anti-inflammatory, and gut-brain axis modulating effects could indirectly support overall brain health and mitigate some of the physiological stressors associated with OUD, including gastrointestinal issues common during withdrawal. Clinically, BPC-157 is often administered subcutaneously at doses between 200-500 mcg daily, typically for 2-4 week cycles. You'll observe that BPC-157 helps to restore physiological balance and cellular resilience, thereby enhancing overall recovery from opioid-induced pathology.

Beyond specific peptides, the broader class of endogenous opioid peptides, such as dynorphins and enkephalins, are crucial in understanding OUD. Dynorphins, for example, are kappa-opioid receptor agonists that can produce dysphoria and contribute to stress-induced relapse. Developing peptides that selectively modulate these systems, perhaps by blocking dynorphin's effects or enhancing pro-social opioid peptides, represents a frontier in OUD treatment. You'll find that modulating these endogenous systems offers a highly targeted approach to addressing the core mechanisms of opioid dependence.

The nuance in utilizing peptides for OUD lies in their ability to address specific neurobiological vulnerabilities that traditional treatments may not fully resolve. While medications like buprenorphine act as partial opioid agonists to prevent withdrawal and reduce cravings, they can also carry their own risks of dependence and side effects. Peptides like oxytocin directly target the emotional and social aspects of withdrawal, while BPC-157 supports systemic healing and neuroprotection. It's important to view these peptides as potential adjunctive treatments, working synergistically with established MATs and behavioral interventions to provide comprehensive support for individuals navigating the complex path of OUD recovery. They are not replacements for MAT but rather complementary tools that can enhance neurobiological resilience and reduce the burden of withdrawal.

Comparing peptide interventions to conventional MAT, such as oral naltrexone (typically 50 mg daily), reveals distinct mechanisms. Naltrexone blocks opioid receptors, preventing both the euphoric effects of opioids and the efficacy of opioid agonists, which can be a barrier for some patients. For a patient with OUD struggling with persistent cravings and anxiety during buprenorphine/naloxone maintenance therapy, consider an adjunctive trial of intranasal oxytocin at 24 IU daily for 8 weeks, monitoring for improvements in craving reduction and emotional regulation, as it targets distinct neurobiological pathways from opioid receptor modulation.

References

[1] Substance Abuse and Mental Health Services Administration. (2023). Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report

[2] Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238.

[3] Lee, M. R., & Weerts, E. M. (2016). Oxytocin for the treatment of drug and alcohol use disorders. Behavioural Pharmacology, 27(7), 603–612.

[4] Rastogi, K., et al. (2024). Oxytocin Reduces Noradrenergic-Induced Opioid-Like Withdrawal Symptoms and Cortisol Levels in Opioid Use Disorder. ScienceDirect, 2667-1743(24), 00108-3.

[5] Sikiric, P. C., et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Pharmaceutical Design, 22(12), 1612–1621.

[6] Sikiric, P. C., et al. (2009). Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice. Journal of Physiology and Pharmacology, 60(Suppl 7), 107–112.

[7] Koob, G. F., & Le Moal, M. (2008). Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society B: Biological Sciences, 363(1507), 3113–3123.